What is MagForce?
MagForce was founded in 1997 and specializes in the development of advanced nanomedicine for innovative cancer therapies. Its nanotechnology-based therapy (NanoTherm™) is being used to treat patients with advanced brain cancer in the European Union and is now being studied in patients with prostate cancer.
What is the MagForce® Clinical Study?
Clinical trials look at new ways to prevent, detect, or treat disease. They are a part of clinical research and at the heart of all medical advances. The goal of clinical trials is to determine if a new test or treatment works and is safe. The MagForce® Clinical Study is being conducted to determine if the NanoTherm™ Thermal Ablation Therapy is safe and effective in the treatment of certain types of prostate cancer.
The current stage of the study, Stage 1, is enrolling 10 subjects who are planning to have a prostatectomy. As we move past Stage 1, we will begin enrolling 100 subjects who have intermediate-risk prostate cancer (as judged by Active Surveillance) and who are good candidates for focal treatment. These subjects will undergo the NanoTherm™ treatment and be followed for up to a year with biopsies to determine if the treatment was effective and no further definitive treatment (e.g. a prostatectomy) will be required.
Why Do People Participate in a Clinical Trial?
People participate in clinical trials for a number of different reasons. Some people participate to help others in that the hope they are helping to contribute to the advancement of science. Some people participate in the hope of receiving a benefit from the experimental treatment for their illness or disease. Others participate in order get additional care and attention from the clinical staff conducting the trial. Finally, some may participate for the financial benefit or other type of compensation that may be available.